Background--Atrial fibrillation (AF) has substantial impacts on healthcare resource utilization. Our objective was to understand the pattern and predictors of cumulative healthcare costs in AF patients after incident diagnosis in an emergency department (ED).
Limitations of the current literature include the heterogeneity between studies in their use of economic models, surveys, administrative data, and patient-reported data, which has produced inconsistencies in cost estimates. 9 Moreover, most of the literature has focused on hospitalization costs, 8, 10 despite most of the treatment for AF actually occurring in the outpatient setting. For example, outpatient and medication costs are estimated to be $1.77 billion (USD) in the United States. 8 Other healthcare sectors such as home care and longterm care may be important components of cumulative cost, given the advanced age of onset of AF and its associated comorbidities. Few studies have examined overall healthcare costs longitudinally from initial AF diagnosis, and these studies have had limited follow-up, from 0.5 to 3 years. [11] [12] [13] [14] These studies have simply explored annual costs or short-term costs, which does not take into consideration the natural history of AF. Studies in cancer and heart failure suggest that there are distinct phases of cumulative cost accumulation that parallel the natural history of the disease, such as that immediately after diagnosis and that before death. 15, 16 It is important to study these phases, because each may have different patient-or system-level predictors of costs. Such information is valuable for decision makers when targeting how to improve the efficiency of care delivery for those with a particular health condition. There have been no studies to date examining these issues in AF. Accordingly, we sought to address this gap in knowledge by estimating per patient longitudinal cumulative costs over time from initial emergency department (ED) diagnosis to death across all healthcare sectors. Ontario is Canada's largest province, with a population of 13 million, all of whom have universal healthcare coverage provided by a single thirdparty payer, the Ontario Ministry of Health and Long Term Care (MOHLTC). Our objectives were to determine if there are clinically relevant phases of cumulative cost accumulation after an index diagnosis of AF and to determine the predictors of healthcare cost in these phases.
Methods
This study was approved by the Institutional Research Ethics Board at Sunnybrook Health Sciences Centre, University of Toronto. Under Ontario's Personal Health Information Protection Act (PHIPA), the need for patient consent was waived.
Data Sources
We conducted our analyses using population-level administrative databases with information on all Ontario residents. These datasets were linked using unique, encoded identifiers and analyzed at the Institute for Clinical Evaluative Sciences (ICES).
The Canadian Institute for Health Information Discharge Abstract Database (CIHI-DAD) was used to identify all acute and chronic care hospitalizations in our cohort. The National Ambulatory Care Reporting System database (NACRS) was used for hospital-based ambulatory care, including ED visits, outpatient surgical procedures, medical day and night care, and high-cost ambulatory clinics data. The Registered Persons Database (RPDB) was used to ascertain death. We obtained postal codes for socioeconomic status and rurality index through Statistics Canada. The Ontario Health Insurance Program (OHIP) fee-for-service claims history was accessed for data on physician services. Comprehensive drug information was obtained from the Ontario Drug Benefit database (ODB) for all patients aged ≥65 years, because the MOHLTC provides full drug coverage only for these patients. The
Canadian Institute for Health Information Same Day Surgery (CIHI-SDS) database was used to obtain patient day surgery information. Long-term care data were from the Continuing Care Reporting System (CCRS) database, which contains demographic, clinical, functional, and resource utilization information on patients in long-term care facilities. Home care information was obtained from the Home Care Database (HCD), which contains administrative data regarding care delivery. Data from the National Rehab System (CIHI-NRS) provided information on inpatient rehabilitation programs.
Study Population
Our cohort consisted of newly diagnosed AF patients based on the International Classification of Diseases Version 10 main diagnosis code I48 in the NACRS database, with their first ED visit between April 1, 2005, and March 31, 2010. We restricted the cohort to patients who were residents of Ontario, who were ≥20 years old, who had valid OHIP identification numbers, who did not have a previous diagnosis of AF within 3 years prior to the index visit, and who survived the index ED visit. We only included patients who were discharged home from the ED after their index presentation, as our algorithm for identification was validated in this population, with a positive predictive value of 93.0% (95% CI 91.6% to 94.2%) and a sensitivity of 96.6% (95% CI 94.1% to 98.2%). 17 For patients with multiple visits during the study timeframe, the first episode was selected as the index event.
Outcomes
The primary outcome was per patient longitudinal cumulative healthcare costs, from the index ED visit to a maximum followup until death or March 31, 2012. We included all available cost sectors, from the perspective of the MOHLTC. We used a bottom-up approach, whereby episodes of care for each sector per patient were identified in administrative databases during the follow-up period. Per-episode cost for hospitalizations, ED visits, same-day surgeries, complex continuing care services, home care services, and long-term care were determined by using resource intensity weights (RIWs) and case-mix methodology. We multiplied the RIW associated with the case-mix group for each episode of care by the mean provincial cost per weighted case (CPWC) for that fiscal year. 18 Costs for physician visits and laboratory tests were obtained directly from the OHIP claims history database, while medication costs were obtained directly from the ODB database. We only included medication costs for patients ≥65 years of age, because MOHLTC coverage was limited to this population. Costs per episode were adjusted to 2013 Canadian dollars using the Consumer Price Index, (http://www.bankofcanada.ca/en/cpi.html) and then summed over the entire follow-period. Cumulative healthcare costs were reported in 30 patient-day intervals.
Phases of Cost
Previous studies by our team and others on heart failure and cancer care have shown that health-related costs are not constant over patient life span but rather have distinct periods of rapid cost accumulation, interspaced by periods of lower cost. 15, 16 We hypothesized that there may be a similar pattern over the lifetime of AF patients, with 3 phases of cost: (1) a post-index ED visit phase of high cost, (2) a stable/chronic phase of relatively constant cost, and (3) a predeath phase of increasing cost. We first conducted exploratory analyses in patient subgroups who died 9 to 12 months post-index, 33 to 36 months post-index, or 57 to 60 months post-index and patients who were alive during the entire follow-up period. We examined their cumulative cost profiles to determine if there were clinically relevant phases of cost for post-index ED visit or predeath. If so, join-point analyses (Join-point regression software version 4.1.1, Statistical Methodology and Applications Branch, Surveillance Research Program, National Cancer Institute) were conducted on each patient subgroup (death at 9 to 12, 33 to 36, and 57 to 60 months post-index) to determine the inflection points that separated cost phases, by using a Monte Carlo permutation method. 19 Based on the inflections in these subgroups, we approximated the inflections for the overall cohort. This is similar to the methodology used in previous publications in studies on heart failure, 16 prostate cancer, 20 and hepatitis C virus. 21 After determining the presence and duration of each phase of cost, the total cost for each patient was allocated to each phase in a hierarchical fashion, where predeath phase cost was assigned first, then to the post-index ED visit, and, finally, all remaining cost to the stable phase. Individual patient costs were assigned to each block within each phase hierarchically, first to the predeath phase, then to the post-index ED visit phase, and finally to the stable/chronic phase. For example, for a patient who died 13 months post-index ED visit, the mean cost for the last 12 months was assigned to the 30 patient-day blocks of the predeath phase, and then the mean cost for the first month was assigned to a 30 patient-day block in the post-index ED visit phase. For a patient who died 34 months post-index ED visit, there were 20 months of cost assigned to the stable/chronic phase after assigning the last 12 months' cost to predeath and the first 2 months to the post-index ED visit. Costs for each of the 20 stable/chronic phase months were then averaged to provide a single 30 patient-day block estimate. Importantly, the cost for any particular episode for each individual patient was assigned to only 1 phase. Once assigned, 30 patient-day mean cost was determined for each phase. For the predeath and post-index phases, a separate 30 patient-day mean cost was estimated for each 30-day interval of each phase. For the stable phase, all remaining costs were averaged to produce a single 30-day mean cost estimate.
Statistical Analysis
We used multivariable hierarchical generalized linear models with a logarithmic link and gamma distribution to determine predictors of cumulative healthcare costs; methods that are consistent with those used in previous studies examining end of life and phases of costs 15, 16 to account for the skewed positive nature of the data. We built separate models for the post-index phase and the predeath phase and tested the appropriateness of a log link and gamma distribution for each model by using the Pregibon link test and modified HosmerLemeshow test, respectively. For the post-index phase of cost, the Pregibon link test indicated that the logarithmic link was appropriate for the generalized linear model (P=0. 19) , and the modified Hosmer-Lemeshow test supported a gamma distribution (P=0.44). For the predeath phase, the Pregibon link test supported the logarithmic link (P=0.394) and the modified Hosmer-Lemeshow test indicated that the gamma distribution was appropriate (P=0.217). The advantage of this type of model is that it accommodates the skewed nature of cost data and produces b-coefficients (rate ratio [RR] ) that are interpreted as the relative increase in mean cost for each increment in the covariate. Covariates included in the 2 models were demographics (age, sex) and comorbidities, including hypertension, diabetes, and kidney/liver dysfunction. We then reran the 2 models using only CHA 2 DS 2 -VASc score as the covariate of interest. The CHA 2 DS 2 -VASc score consists of congestive heart failure/left ventricular dysfunction, hypertension, age ≥75 years (doubled), diabetes, stroke (doubled)-vascular disease, age 65 to 74 years, and sex category (female). We chose the CHA 2 DS 2 -VASc score because it is inclusive of common clinically relevant major and nonmajor risk factors for stroke, 22 and it has been validated in multiple cohort studies. 23 We used SAS version 9.3 (SAS Institute Inc) for statistical analyses and STATA version 13.1 for goodness-of-fit and goodness-of-link tests.
Results

Study Population
There was a total of 61 112 ED visits for AF in Ontario, Canada, between April 1, 2005, and March 31, 2010 ( Figure 1 ). After applying exclusions, our final cohort consisted of 17 980 patients. Baseline characteristics are shown in Table 1 . Mean age of the patients was 65.7 years, and 45.8% were female. The majority of patients had hypertension (60.7%), while only 18.8% had diabetes mellitus. Approximately 1.2% had a previous stroke. In regard to stroke risk, 35.8% of patients had low CHA 2 DS 2 -VASc scores (scores 0 to 1), and the majority of patients had scores <5 (90.2%). In our cohort, 17.1% of patients died during the 3.9 years of followup. A total of 1055 patients (5.9%) died within 1 year of their index ED presentation.
Phases of Cost
In our exploratory analyses, we confirmed that cumulative cost curves for AF were defined by discrete cost phases ( Figure 2 ). Inflection points separated the post-index ED visit and stable/chronic phases at 2 months post-index, and the stable/chronic and predeath phases at 12 months predeath. There were two 30 patient-day blocks of consecutive cost for the post-index phase, and 12 blocks for the predeath phase. Figure 3 shows the mean cost per patient for each 30-day block of each phase, and Table 2 shows the costs divided into components of cost. Of the 3 phases, total cost was highest in the predeath phase. In the predeath phase, total cost increased by 75% across 30 patient-day blocks, from 12 months predeath ($1984, 95% CI $1816 to $2152) to 1 month predeath ($8050, 95% CI $7666 to $8434). For the post-index phase, the mean total cost per patient was highest at 1 month post-index ($1876, 95% CI $1822 to $1931) and decreased substantially by 46% at 2 months post-index ($872, 95% CI $828 to $916). For the stable/chronic phase, mean total cost was the lowest of the 3 phases, at $640 (95% CI $624 to $655) per month. Acute hospitalization cost was the predominant driver of cost in the predeath phase (72% of all costs for 1 month predeath). In the post-index phase, cost was more evenly distributed among physician services, acute hospitalizations, and ED visits (32%, 31%, and 24% of all costs for 1 month post-index, respectively). For the stable/chronic phase, acute hospitalizations were the largest contributor to total costs (29%), but physician services (23% of all costs) and medications (16%) also remained high.
Predictors of Cost
Several patient characteristics were significant predictors of total per patient cost. In the post-index phase, per patient cost was more likely to be higher for patients who were older (RR 1.019, 95% CI 1.018 to 1.020, P<0.0001) or who had a history of diabetes mellitus, congestive heart failure, Table 3 ) were associated with increased costs. When our models were repeated with only the CHA 2 DS 2 -VASc score, we found that the score was a strong predictor of per-patient cost for both post-index and predeath analyses. There was a general gradient of cost with increasing comorbidity, as reflected by a higher CHA 2 DS 2 -VASc score (RR 5.08 and 1.91 for a score of 7 compared with a score of 0, respectively).
Discussion
The authors examined per-patient longitudinal cumulative cost from initial ED visit diagnosis across all healthcare sectors, by determining clinically relevant phases of total cost and the predictors of cost in these phases. We found that cost was highest in the predeath phase, due mainly to acute hospitalization cost, and increased as patients approached death. Cost was next highest in the post-index phase, with physician services, acute hospitalizations, and ED visits as the highest costs, and cost was greater during the first month post-index. Cost was lowest in the stable/chronic phase and was mainly attributable to acute hospitalizations, physician services, and medications. Comorbidities contributed to higher healthcare cost, and CHA 2 DS 2 -VASc score was a particularly strong predictor.
Previous studies have determined that AF-related medical costs are high. A recent systematic review estimated a mean overall annual per-patient cost of AF at $2000 to $14 200 USD in the United States, using both prevalent and incident AF cohorts. 24 Our study provides a more complete picture of individual patient cumulative costs, as we examined longitudinal cost from index AF diagnosis to death and incorporated the impact of the natural history of AF by examining phases of cost. Of the studies in the literature that examined longitudinal costs from AF diagnosis, [11] [12] [13] [14] we are only aware of studies where follow-up was short term (0.5 to 3 years), which prevents direct comparisons to our results. Our study highlights that simply examining annual costs is potentially misleading, as costs are highly dependent on the phase of the disease, with a 10-fold difference in monthly costs between the stable phase and predeath phase. In terms of contributors of cost in AF, systematic reviews have determined that hospitalization is the largest cost, 9, 24 accounting for 50% to 70% of mean total cost. 24 Our phasebased AF costing method provides additional insights, as we found that contributors of cost were also highly dependent on the disease phase. While hospitalization was a large contributor of cost in all phases in our study, it was only within the same range of total cost of previous studies during the predeath phase, where hospitalizations contributed to 51% of total cost. Other cost components were also predominant contributors of cost during the stable/chronic and post-index phases.
Our phase-based costing approach is the first of its kind for AF costing, and to our knowledge this method has only been previously applied to cancer and heart failure. 15, 16 Cost per phase and the contributors of cost differ depending on the diseases studied thus far. A previous study by our research team found that mean total cost per phase was highest in the predeath phase for heart failure clinic patients 16 ; this is similar with our results in AF. In contrast to our AF study, hospitalization was overwhelmingly the largest contributor of cost for heart failure clinic patients, representing >80% of total healthcare costs for patients in the predeath and posthospital discharge phases and 50% of total costs in the stable/chronic phase. 16 A study by Brown and colleagues found that for colorectal cancer, overall total cost was highest for the predeath phase, as is consistent with these 2 studies, although monthly mean cost was highest for the post-index phase, 15 rather than for predeath as in the current study.
Unfortunately, cost was not broken down into its components, so no comparison could be made to AF costing components.
It is important to note that our costing approach is not specific to the cost of treating AF but is instead closely tied with other comorbidities, and so it can be thought of as the cost of patients with AF. It is well known that comorbidities are commonly associated with AF, especially cardiovascular conditions such as ischemic heart disease, heart failure, and hypertension. 25, 26 A recent retrospective observational study reported that 98% of the AF population had at least 1 other comorbidity, and 63% had ≥4 comorbidities, 45% and 21% had a moderate or high comorbidity burden, and 45% had a moderate risk for stroke (CHADS 2 scores of ≥2). 25 The large influence of comorbidities is reflected in our AF costing results, as we found that comorbidities were the largest predictors of AF-related cost. The CHA 2 DS 2 -VASc score was a particularly important predictor, a result that is consistent with another study that examined predictors of AF cost. 27 
Limitations
Our study has several potential limitations that merit discussion. First, we did not take on a societal perspective but rather that of the third-party payer for the province. As such, there were costs that we excluded. For example, we could not include medication costs for patients <65 years old, as Ontario only provides comprehensive coverage for patients ≥65 years old. Moreover, we did not include patient out-ofpocket costs or loss of productivity related to missed work. Inclusion of these components would have driven AF costs higher. However, given the elderly age of most AF patients, we do not believe this would have made a large difference in our conclusions. Second, we limited our analyses to 3 phases and did not look at other potentially important clinical events such as the occurrence of a major stroke or major bleed. These are important foci for further research. Third, we did not include location of death (ie, hospital, home) in our analyses. Patients who die in hospital would incur higher immediate predeath costs than those who die at home. If characteristics of patients who die at home differ from those of other patients in the cohort, then location of death can be an important predictor of healthcare costs. Unfortunately, our available databases do not provide the location of death, so we could not include this covariate. Fourth, there are limitations to existing methods for estimating healthcare costs and implications for the choice of method of analysis. We used generalized linear models, which are generally an improvement to the transformed linear models that were previously commonly used. 28 A criticism of generalized linear models is that they can be imprecise and lack robustness, consistency, and efficient methods. 28 Therefore, applying the appropriate link function and distribution to the model is important. However, there are issues with the diagnostic tests used to determine the optimal model. The modified Hosmer-Lemeshow test is prone to influential outliers, 28 the value of the statistic depends on the choice of cutpoint that defines the groups, and the test can have low power for detecting lack-offit. 29 The Pregibon test and other link tests are more parsimonious tests, but mildly influential observations can result in false-positive and -negative results. 28 New alternative methods for estimating costing have been developed, but further research is needed to improve these methods. 28 Finally, endogeneity in costs is a well-recognized phenomenon, in particular for costs at the end of life, where costs are likely to be impacted by unmeasured confounders and other selection biases. As such, in light of these features of cost data, compounded by the observational nature of our study, we cannot assume causality between predictors of cost and cost; therefore, our findings should be considered hypothesis generating rather than conclusive.
Conclusion
In our phase-based longitudinal costing approach to AFrelated costs in patients from AF diagnosis to death, we have identified 3 distinct phases of costs and found that costs were highest in the predeath phase, where hospitalization cost was a far greater contributor to total cost than in other phases.
Further research is needed on methods to incorporate these phase based costs into cost-effectiveness analyses for AF therapies. 
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